Member Info for desamax

See RMMs respected calculations.

Can only sell 10k atm on HL might be just me but can’t get quote for anything above.

Possibly happened here last week with the patent rns, also sar or their board tweet news that’s found on here by the informed detective posters.

No interviews since, now why cold that be ??

Let’s recap last year’s trading update Tim’s interview
Note the statement around 2.20 in.

https://m.youtube.com/watch?v=h6zdOkooHzY

I’m banking on a Rob ZImmerman FOI request related to Sareums agile grant progress.
Here’s one he requested earlier this year......


Mr Rob Zimmerman
Sent by email: xxxxxxxxxxxxxxxxxxxxxxx@xxxxxxxxxxxxxx.xxx


15 June 2021



Dear Mr Zimmerman,

Freedom of Information request: FOI2021/00263

Thank you for your Freedom of Information request received on the 25 May in which you requested the fol owing:

Your request:

Sareum Holdings - Investigating the therapeutic potential of TYK2 / JAK1 inhibitor SDC-1801 in severe phase
Covid-19

The captioned UKRI funded study is described as 'Collaborative R&D'. Would you please confirm the identities of
all parties involved in the collaboration.

https://gtr.ukri.org/projects?ref=83721


Our response:

I can confirm UK Research and Innovation (UKRI) hold the information relevant to your request. Please see the
information below.

Project 83721, “Investigating the therapeutic potential of TYK2 / JAK1 inhibitor SDC-1801 in severe phase Covid-
19” is a single participant project, with Sareum Limited being the only participant.

The term ‘Col aborative R&D’ is the project category assigned to the overall competition, however this competition
was open to single applicants and col aborative projects.

Information on all the successful projects for the competition UKRI Ideas to Address COVID-19: Innovate UK de
minimis Aug 20201 is available as part of the Innovate UK funding competition winners2 transparency data.

Note he only post during office hours. He is here to be disruptive and deflect the informed post. He is definitely ‘at the get up’ shame really because he could have made himself a few bob. But you can’t educate a mug.

More......

SDC-1802 is advancing behind SDC-1801 in preclinical development. Formulation work for oral dosing is complete and toxicology studies and further manufacturing work are planned over the coming months.
· In October 2019, Sareum presented new findings showing that SDC-1802, dosed orally as a monotherapy and in combination with chemotherapy, significantly reduces tumour growth in models of solid tumours and blood cancers. SDC-1802 was found to act through a novel immunotherapeutic mechanism of action. These findings were presented at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) International Conference.
TYK2/JAK1 Inhibitors for treating symptoms of Covid-19
In its Half-Yearly report published on 26 March 2020, the Company noted that it would investigate grant funding opportunities to assess the potential use of its TYK2/JAK1 inhibitors to address the severe inflammatory responses (the "cytokine storm") and potentially fatal respiratory symptoms of Covid-19 and other viral infections.
· A grant application to fund preliminary laboratory studies designed to investigate the ability of its TYK1/JAK2 inhibitors to modulate (down-regulate) the overactive immune system in relevant cellular and mouse disease models has been submitted to UK Research and Innovation (UKRI) and a response is expected by the end of October 2020.
· These preliminary studies have been designed as a potential first step towards clinical studies, pending success and further funding.
FLT3+Aurora Inhibitors
On 26 March 2020, Sareum announced it entered a global licensing deal for its FLT3+Aurora kinase inhibitor programme targeting blood cancers with a China-based specialty pharmaceutical company (the "Licensee"). The Licensee will fund all future development activities for licensed FLT3+Aurora kinase inhibitors and has been granted the sole rights to commercialise any resulting products worldwide.

From 2020 trading update

Key Objectives
· Complete preclinical (IND-enabling) studies with at least one candidate by the end of 2020.
· Decide on the initial target indications during 2H 2020 as part of preparation for first-in-human studies.
· Build a robust preclinical data package to support ongoing partnering activities.
· Continue and advance initial discussions with potential partners to secure commercial licences for its assets when they reach late preclinical or early clinical stages.
SDC-1801 (autoimmune diseases)
SDC-1801 and related molecules have shown promising activity in autoimmune disease models, including psoriasis, rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus (SLE).
· SDC-1801 has demonstrated excellent tolerability in toxicology studies in rodents and work is continuing towards completing the dose-finding and longer-term toxicology studies ahead of human trials.
· A robust manufacturing route has been developed to produce active ingredient under GMP (Good Manufacturing Practice) conditions for both preclinical and clinical studies.
· A formulation that will successfully deliver a therapeutic dose level has been identified, however the Company is required to deliver very high doses to SDC-1801 in order to identify a toxic dose level (maximum tolerated dose), and formulation studies for this are still ongoing.
· Encouraging preclinical data reported with Sareum's TYK2/JAK1 inhibitors in SLE disease models. These studies were conducted by co-development partner SRI International (Menlo Park, CA, USA) under a US Department of Defense (DoD) grant and recently published on the website of the Defense Technical Information Center.
SDC-1802 (cancer immunotherapy)
SDC-1802 and related TYK2/JAK1 inhibitors have shown encouraging anti-tumour activity in multiple cancer disease models. Sareum retains global commercialisation rights for TYK2/JAK1 inhibitors with profiles optimised for oncology and immuno-oncology applications.

Ahfam is it not 3.5 million invested via two HNWI?

Anyone think we will get a presentation with the formal Q & A ? Or is there any reasonable way for the board to avoid one this year?

Same, i thought I was seeing things when I went back to look for the date. It was the same date James posted, can’t see it now.

None showing from 3.06pm onwards on my phone.

On the ask HL

Tiny was you being realistic when you bought in @ 9p and then got even more realistic predicting 2-5p ?
No wonder your so bitter, you couldn’t call a bingo number.

Will we get the end of day bounce around like we saw yesterday, some interesting late reported buys came in. No news on them today, is there a timeframe for announcement via RNS for either warrants or TR2?

LTHs soon?

https://m.youtube.com/watch?v=U1Tt58B0iG4

Happy birthday SOG, thanks for you well versed input to this excellent board. Long may it continue.
Enjoy your day.

3.15% up on Google, I’m happy with that. “I think I’m alright here” lol

Bounced about at the end HL showing 4.05% up on the day.